Skip to content
Dendreon
  • News
  • Contact Us
  • About
  • Science and Services
    • Cellular Therapy Manufacturing
    • Provenge Immunotherapy
  • Publications
  • Careers
News Real-World Study Of 6,000+ Medicare Patients With Advanced Prostate Cancer Shows Adding PROVENGE® (Sipuleucel-T) To Treatment Regimen Reduced Risk Of Death By 45%
February 13, 2020

Real-World Study Of 6,000+ Medicare Patients With Advanced Prostate Cancer Shows Adding PROVENGE® (Sipuleucel-T) To Treatment Regimen Reduced Risk Of Death By 45%

  • News Type: Press Releases
Read More
LinkedInShareTweet
Dendreon
© Dendreon Pharmaceuticals LLC. All Rights Reserved. 2023.
  • Privacy Policy
  • Legal Notice
  • Site Map
  • Linkedin
  • Facebook
  • Twitter